Perceptive Advisors Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$5.12B
Q ending 2026-03-31
Prior quarter
$5.61B
Q ending 2025-12-31
Change
-8.8% QoQ · +80.8% YoY
Positions
94
reported holdings
Largest positions
All 94 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Praxis Precision Medicines I | PRAX | Shares | $656.0M | 2.0M |
| Celcuity Inc | CELC | Shares | $356.9M | 3.1M |
| Ascendis Pharma A/S | Shares | $350.3M | 1.5M | |
| Roivant Sciences Ltd | Shares | $229.5M | 8.3M | |
| Centessa Pharmaceuticals Plc | 260 | Shares | $208.9M | 5.3M |
| Rhythm Pharmaceuticals Inc | RYTM | Shares | $206.4M | 2.4M |
| Spyre Therapeutics Inc | SYRE | Shares | $190.8M | 3.8M |
| Nuvalent Inc | 5AX | Shares | $161.9M | 1.6M |
| Edgewise Therapeutics Inc | EWTX | Shares | $139.4M | 4.4M |
| Protagonist Therapeutics Inc | PTGX | Shares | $129.7M | 1.2M |
| Apogee Therapeutics Inc | APGE | Shares | $129.7M | 1.5M |
| Travere Therapeutics Inc | TVTX | Shares | $123.1M | 4.1M |
| Amylyx Pharmaceuticals Inc | AMLX | Shares | $115.2M | 8.3M |
| Immatics N.V | Shares | $102.2M | 10.4M | |
| Relay Therapeutics Inc | RLAY | Shares | $97.0M | 9.8M |
| Inhibrx Biosciences Inc | INBX | Shares | $97.0M | 1.4M |
| Meiragtx Hldgs Plc | Shares | $89.3M | 10.3M | |
| Zymeworks Inc | ZYME | Shares | $87.9M | 3.5M |
| Solid Biosciences Inc | SLDB | Shares | $85.7M | 11.9M |
| Dyne Therapeutics Inc | DYN | Shares | $84.6M | 4.7M |
| Biocryst Pharmaceuticals Inc | BCRX | Shares | $70.8M | 7.4M |
| Oruka Therapeutics Inc | ORKA | Shares | $68.4M | 1.4M |
| Artivion Inc | AORT | Shares | $60.0M | 1.6M |
| Nurix Therapeutics Inc | NRIX | Shares | $57.5M | 3.7M |
| Moderna Inc | MRNA | Put | $50.8M | 1.0M |
| Nautilus Biotechnology Inc | NAUT | Shares | $48.9M | 12.6M |
| Cytomx Therapeutics Inc. | CTMX | Shares | $47.5M | 10.1M |
| Alto Neuroscience Inc | ANRO | Shares | $45.2M | 2.0M |
| Engene Holdings Inc | Shares | $39.7M | 5.8M | |
| Immunovant Inc | IMVT | Shares | $39.7M | 1.6M |
| Intuitive Surgical Inc | ISRG | Shares | $39.4M | 85K |
| Ionis Pharmaceuticals Inc | IONS | Shares | $37.8M | 504K |
| Day One Biopharmaceuticals I | DAWNGBX | Shares | $37.6M | 1.8M |
| Abivax Sa | ABVX | Shares | $36.6M | 329K |
| Corvus Pharmaceuticals Inc | CRVS | Shares | $33.5M | 2.3M |
| Repligen Corp | RGEN | Shares | $33.1M | 281K |
| Jazz Pharmaceuticals Plc | Shares | $32.1M | 170K | |
| Damora Therapeutics Inc | DMRA | Shares | $31.7M | 1.2M |
| X4 Pharmaceuticals Inc | XFOR | Shares | $27.8M | 6.7M |
| Guardant Health Inc | GH | Shares | $27.7M | 300K |
| Bright Minds Biosciences Inc | DRUG | Shares | $27.5M | 378K |
| Invivyd Inc | IVVD | Shares | $27.1M | 20.9M |
| Sionna Therapeutics Inc | SION | Shares | $26.4M | 658K |
| Axsome Therapeutics Inc. | AXSM | Shares | $25.3M | 150K |
| Revolution Medicines Inc | RVMD | Shares | $25.1M | 259K |
| Sab Biotherapeutics Inc | SABS | Shares | $24.6M | 6.4M |
| Belite Bio Inc | BLTE | Shares | $24.2M | 152K |
| Tenax Therapeutics Inc | TENX | Shares | $23.2M | 1.4M |
| Axogen Inc | AXGN | Shares | $23.1M | 697K |
| Viridian Therapeutics Inc | VRDN | Shares | $22.9M | 1.2M |
| Orchestra Biomed Hldgs Inc | OBIO | Shares | $21.4M | 5.0M |
| Rapport Therapeutics Inc | RAPP | Shares | $21.1M | 674K |
| Dbv Technologies S A | DBVT | Shares | $20.1M | 964K |
| Leonabio Inc | LONA | Shares | $19.1M | 1.9M |
| Anteris Technologies Global | AVR | Shares | $19.0M | 3.4M |
| Sutro Biopharma Inc | STRO | Shares | $17.8M | 715K |
| Tango Therapeutics Inc | TNGX | Shares | $16.9M | 808K |
| Contineum Therapeutics Inc | CTNM | Shares | $16.4M | 1.3M |
| Celcuity Inc | CELC 2.75 08/01/31 | Principal | $15.9M | 6.5M |
| Palisade Bio Inc | PALI | Shares | $15.6M | 8.9M |
| Oculis Holding Ag | Shares | $13.1M | 494K | |
| Irhythm Holdings Inc | IRTC | Shares | $12.4M | 105K |
| Adagio Med Hldgs Inc | ADGM | Shares | $11.0M | 9.9M |
| Evommune Inc | EVMN | Shares | $10.3M | 448K |
| Phathom Pharmaceuticals Inc | PHAT | Shares | $10.3M | 925K |
| Neumora Therapeutics Inc. | NMRA | Shares | $10.0M | 5.1M |
| Omada Health Inc | OMDA | Shares | $9.9M | 786K |
| Neurocrine Biosciences Inc | NBIX | Shares | $8.6M | 65K |
| Beta Bionics Inc | BBNX | Shares | $8.4M | 843K |
| Opus Genetics Inc | IRD | Shares | $8.4M | 1.8M |
| Billiontoone Inc | BLLN | Shares | $7.2M | 92K |
| Twist Bioscience Corp | TWST | Shares | $7.1M | 150K |
| Surrozen Inc | SRZN | Shares | $6.7M | 229K |
| Agomab Therapeutics Nv | AGMB | Shares | $6.3M | 600K |
| Evolus Inc | EOLS | Shares | $5.3M | 1.3M |
| Cogent Biosciences Inc | COGT | Shares | $4.7M | 121K |
| Ocular Therapeutix Inc | OCUL | Call | $4.2M | 500K |
| Adma Biologics Inc | ADMA | Shares | $4.2M | 467K |
| Inhibikase Therapeutics Inc | IKT | Shares | $3.9M | 2.3M |
| Crescent Biopharma Inc. | Shares | $3.8M | 207K | |
| Apellis Pharmaceuticals Inc | APLS | Shares | $3.3M | 81K |
| Outset Med Inc | OM | Shares | $3.2M | 833K |
| Edesa Biotech Inc | EDSA | Shares | $2.9M | 563K |
| Adaptive Biotechnologies Cor | ADPT | Shares | $2.1M | 153K |
| Avalo Therapeutics Inc | AVTX | Shares | $2.1M | 140K |
| Connect Biopharma Hldgs Ltd | Shares | $2.1M | 793K | |
| Corcept Therapeutics Inc | CORT | Shares | $2.0M | 50K |
| Medline Inc | MDLN | Shares | $1.2M | 28K |
| Palatin Technologies Inc | PTN | Shares | $1.1M | 62K |
| Cumberland Pharmaceuticals I | CPIX | Shares | $640K | 197K |
| Revolution Medicines Inc | RVMDW | Shares | $448K | 250K |
| Exagen Inc | XGN | Shares | $345K | 115K |
| Ensysce Biosciences Inc | ENSC | Shares | $47K | 87K |
| Surrozen Inc | SRZNW | Shares | $3K | 167K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.